<div id="readability-page-1"><div><p>(MT Newswires) -- China Meheco Group's (SHA:600056) unit, Tianfang Pharmaceutical, received approval from the Chinese drug administrator for its drug supplementary application for lincomycin hydrochloride injection after the drug passed regulatory evaluation, according to a Shanghai bourse filing on Wednesday.</p><p> The drug, which is mainly used for the treatment of severe infections caused by susceptible strains such as streptococci, pneumococci, and staphylococci, was tested for its consistency in quality and efficiency.</p><p>The Chinese drugmaker's shares dropped less than 2% during the afternoon trade.</p></div></div>

中国医药

<p>（MT Newswires）-- 中国医药（SHA:600056）旗下的天方药业在周三的上海证券交易所公告中表示，已获得中国药品监管部门对其林可霉素盐酸盐注射液的药品补充申请的批准，该药品在监管评估中通过。该药物主要用于治疗由易感菌株（如链球菌、肺炎球菌和金黄色葡萄球菌）引起的严重感染，经过了质量和效率的一致性测试。该中国制药公司的股票在下午交易中下跌了不到 2%</p>

中国医药的子公司在通过评估后，获得了林可霉素盐酸注射液补充申请的批准